## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.9% below STRENGTH zone (4.0-10.0%); PEG 4.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($663.58)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. $1000 Invested In IDEXX Laboratories 20 Years Ago Would Be Worth This Much Today**
- Source: Sahm | 20251218T010932 | Bullish | Relevance: 100%
- IDEXX Laboratories (NASDAQ: IDXX) has shown significant outperformance over the past two decades, yielding an average annual return of 12.05%. An initial investment of $1000 made 20 years ago in IDXX stock would now be valued at $9,606.21. This article highlights the substantial impact of compounded returns on investment growth over time.

**2. Texas Permanent School Fund Corp Has $3.55 Million Stake in IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251219T104032 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp recently decreased its stake in IDEXX Laboratories Inc. by 25.6%, now holding 6,623 shares valued at $3.55 million, despite institutional investors collectively owning a significant portion of the company. A key executive also reduced her holdings, even as IDEXX reported strong quarterly earnings, beat analyst estimates, and received a "Moderate Buy" consensus rating with an average target price of $763.50. The company's positive financial performance and analyst sentiment suggest continued strength despite some institutional and insider selling.

**3. How Idexx Laboratories Inc. (IDXX) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251218T045800 | Somewhat-Bearish | Relevance: 100%
- This article analyzes Idexx Laboratories Inc. (IDXX) using AI models to provide insights into rotational strategy timing. It highlights divergent sentiment across various time horizons, indicating choppy conditions, and presents an exceptional 26.5:1 risk-reward short setup. The analysis includes position, momentum, and risk-hedging strategies with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis.

**4. IDEXX Laboratories, Inc. $IDXX Shares Purchased by Orion Porfolio Solutions LLC**
- Source: MarketBeat | 20251217T112021 | Bullish | Relevance: 100%
- Orion Portfolio Solutions LLC significantly increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 116.6% in Q2, bringing its total to 10,718 shares valued at approximately $5.75 million. This follows strong quarterly results where IDEXX surpassed earnings and revenue expectations and provided optimistic FY2025 guidance. Several other institutional investors also increased their stakes, with analysts maintaining a "Moderate Buy" consensus rating and an average price target of $763.50.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.16 signals overvaluation risk, limited margin of safety. Forward P/E 48.6x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.0B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.16 |
| Forward P/E | 48.6 |
| Current P/E | 54.3 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.9% to -2.9% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.22x) but short-term weakness (below SMA20). MACD histogram bearish (-4.51), momentum weakening. RSI neutral at 48. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +SBH (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.91% (CS: 22) | Weak |
| RSI_14 | 48.5 | Neutral |
| MACD Histogram | -4.51 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.224x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $700.34
- **Stop Loss:** $663.58 (5.2% risk)
- **Target:** $737.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 32
- **Position Value:** $22,410.88
- **Portfolio %:** 22.41%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*